Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00609817 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy Study of GCS-100LE in the Treatment of Multiple Myeloma
A Phase 1 study, sponsored by La Jolla Pharmaceutical Company.
- Terminated
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT00609817: Clinical Trial Phase 1 study, sponsored by La Jolla Pharmaceutical Company.
NCT00609817 is a Phase 1 study that was terminated before completion, run by La Jolla Pharmaceutical Company. The registered enrollment target is 9 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00609817, a Phase 1 study, was terminated before completion, sponsored by La Jolla Pharmaceutical Company.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
A Phase 1, open-label, dose escalation, multi-center study in patients who have been diagnosed with multiple myeloma and who have relapsed or have refractory/relapsed disease after treatment with at least 2 prior therapies.
Interventions
- DRUG GCS-100
- DRUG Bortezomib/Dexamethasone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2008-05 |
| Est. Completion | 2009-04 |
| Phase | Phase 1 |
Why NCT00609817 stopped before completion
NCT00609817 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (85% lower).
The record links to 0 conditions, and to 2 interventions - of which GCS-100 is the first listed.
NCT00609817 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00609817 about?
NCT00609817 is a clinical study titled "Safety and Efficacy Study of GCS-100LE in the Treatment of Multiple Myeloma". A Phase 1, open-label, dose escalation, multi-center study in patients who have been diagnosed with multiple myeloma and who have relapsed or have refractory/relapsed disease after treatment with at least 2 prior therapies.
What is the current status of trial NCT00609817?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2008-05. Estimated completion is 2009-04.
What interventions are being tested in trial NCT00609817?
The interventions under investigation include: GCS-100 (DRUG), Bortezomib/Dexamethasone (DRUG).
Who is sponsoring clinical trial NCT00609817?
This trial is sponsored by La Jolla Pharmaceutical Company, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00609817's enrollment target sits among peer trials
9 1955th of 2000 higher than 42 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia